News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
Flagship Ventures Fund V General Partner LLC
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/15/2023 |
4
| Flagship Ventures Fund V General Partner LLC (10% Owner) has filed a Form 4 on Sigilon Therapeutics, Inc.|
Txns:
| Unknown transaction of 683,760 shares
@ $14.92, valued at
$10.2M
Unknown transaction of 113,960 shares
@ $14.92, valued at
$1.7M
|
|
| 08/14/2023 |
13F-NT
| Form 13F-NT - Quarterly report filed by institutional managers, Notice: |
| 06/08/2023 |
4
| Flagship Ventures Fund V General Partner LLC (10% Owner) has filed a Form 4 on Sana Biotechnology, Inc.|
Txns:
| Sold 181,461 shares
@ $6.3061, valued at
$1.1M
Sold 22,297 shares
@ $6.3061, valued at
$140.6k
Sold 177,240 shares
@ $6.2397, valued at
$1.1M
Sold 22,760 shares
@ $6.2397, valued at
$142k
|
|
| 05/26/2023 |
4
| Flagship Ventures Fund V General Partner LLC (10% Owner) has filed a Form 4 on Sana Biotechnology, Inc.|
Txns:
| Sold 308,290 shares
@ $6.5652, valued at
$2M
Sold 39,580 shares
@ $6.5652, valued at
$259.9k
Sold 102,245 shares
@ $6.3522, valued at
$649.5k
Sold 13,127 shares
@ $6.3522, valued at
$83.4k
Sold 72,670 shares
@ $6.2265, valued at
$452.5k
Sold 9,330 shares
@ $6.2265, valued at
$58.1k
|
|
| 02/14/2023 |
13F-NT
| Form 13F-NT - Quarterly report filed by institutional managers, Notice: |
| 11/14/2022 |
13F-NT
| Form 13F-NT - Quarterly report filed by institutional managers, Notice: |
| 09/16/2022 |
4
| Flagship Ventures Fund V General Partner LLC (10% Owner) has filed a Form 4 on Codiak BioSciences, Inc.|
Txns:
| Bought 722,590 shares
@ $0
Bought 210,743 shares
@ $0
Bought 722,590 options to buy
@ $1.875, valued at
$1.4M
Bought 210,743 options to buy
@ $1.875, valued at
$395.1k
|
|
| 08/15/2022 |
13F-NT
| Form 13F-NT - Quarterly report filed by institutional managers, Notice: |
| 05/16/2022 |
13F-NT
| Form 13F-NT - Quarterly report filed by institutional managers, Notice: |
| 02/14/2022 |
13F-NT
| Form 13F-NT - Quarterly report filed by institutional managers, Notice: |
| 11/15/2021 |
13F-NT
| Form 13F-NT - Quarterly report filed by institutional managers, Notice: |
| 08/16/2021 |
13F-NT
| Form 13F-NT - Quarterly report filed by institutional managers, Notice: |
| 08/05/2021 |
4
| Flagship Pioneering Inc. (10% Owner) has filed a Form 4 on Omega Therapeutics, Inc.|
Txns:
| Converted 1,088,470 shares
@ $0
Converted 5,896,386 shares
@ $0
Converted 8,396,825 shares
@ $0
Bought 220,588 shares
@ $17, valued at
$3.7M
Converted 970,588 shares
@ $0
Converted 4,852,943 shares
@ $0
Bought 661,764 shares
@ $17, valued at
$11.2M
Converted 1,323,529 shares
@ $0
Bought 294,117 shares
@ $17, valued at
$5M
Converted 4,112,000 convertible preferred
@ $0
Converted 22,275,232 convertible preferred
@ $0 |
|
| 07/29/2021 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 05/17/2021 |
13F-NT
| Form 13F-NT - Quarterly report filed by institutional managers, Notice: |
| 03/23/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/16/2021 |
13F-NT
| Form 13F-NT - Quarterly report filed by institutional managers, Notice: |
| 02/10/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/03/2021 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 12/10/2020 |
4
| Flagship Ventures Fund V General Partner LLC (10% Owner) has filed a Form 4 on Sigilon Therapeutics, Inc.|
Txns:
| Converted 8,888,888 shares
@ $0
Converted 1,481,481 shares
@ $0
Converted 4,444,444 convertible preferred
@ $0
Converted 4,074,074 convertible preferred
@ $0
Converted 370,370 convertible preferred
@ $0
Converted 1,481,481 convertible preferred
@ $0 |
|
| 12/03/2020 |
3
| Flagship Ventures Fund V General Partner LLC (10% Owner) has filed a Form 3 on Sigilon Therapeutics, Inc. |
| 11/16/2020 |
13F-NT
| Form 13F-NT - Quarterly report filed by institutional managers, Notice: |
| 10/29/2020 |
4
| Flagship Ventures Fund V General Partner LLC (10% Owner) has filed a Form 4 on Foghorn Therapeutics Inc.|
Txns:
| Converted 4,054,054 shares
@ $0
Converted 4,504,504 shares
@ $0
Converted 722,320 shares
@ $0
Bought 50,000 shares
@ $16, valued at
$800k
Converted 1,441,441 shares
@ $0
Bought 50,000 shares
@ $16, valued at
$800k
Converted 1,801,801 shares
@ $0
Bought 50,000 shares
@ $16, valued at
$800k
Converted 7,500,000 convertible preferred
@ $0
Converted 8,333,333 convertible preferred
@ $0
Converted 1,336,293 convertible preferred
@ $0 |
|
| 10/22/2020 |
3
| Flagship Ventures Fund V General Partner LLC (10% Owner) has filed a Form 3 on Foghorn Therapeutics Inc. |
| 10/20/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/13/2020 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 08/13/2020 |
13F-NT
| Form 13F-NT - Quarterly report filed by institutional managers, Notice: |
| 05/14/2020 |
13F-NT
| Form 13F-NT - Quarterly report filed by institutional managers, Notice: |
| 02/13/2020 |
13F-NT
| Form 13F-NT - Quarterly report filed by institutional managers, Notice: |
| 11/14/2019 |
13F-NT
| Form 13F-NT - Quarterly report filed by institutional managers, Notice: |
| 08/13/2019 |
13F-NT
| Form 13F-NT - Quarterly report filed by institutional managers, Notice: |
| 05/14/2019 |
13F-NT
| Form 13F-NT - Quarterly report filed by institutional managers, Notice: |
| 03/06/2019 |
4
| Flagship Ventures Fund V General Partner LLC (10% Owner) has filed a Form 4 on Kaleido Biosciences, Inc.|
Txns:
| Converted 1,545,852 shares
@ $0
Converted 4,637,555 shares
@ $0
Converted 426,240 shares
@ $0
Converted 639,360 shares
@ $0
Converted 321,337 shares
@ $0
Converted 964,010 shares
@ $0
Converted 1,285,347 shares
@ $0
Converted 625,625 shares
@ $0
Converted 625,625 shares
@ $0
Bought 266,667 shares
@ $15, valued at
$4M
Bought 333,333 shares
@ $15, valued at
$5M
|
|
| 02/27/2019 |
3
| Flagship Ventures Fund V General Partner LLC (10% Owner) has filed a Form 3 on Kaleido Biosciences, Inc. |
|
|
|